XOMA(XOMA) - 2025 Q2 - Quarterly Results

Exhibit 99.1 | Partner | Event | | --- | --- | | Rezolute | In May, the company announced the U.S. Food and Drug Administration (FDA) granted Breakthrough | | | Therapy Designation (BTD) to its investigational therapy, ersodetug, for the treatment of hypoglycemia | | | caused by tumor HI.1 | | | In May, Rezolute announced the completion of enrollment in the Phase 3 sunRIZE study. Topline data are | | | anticipated in December of 2025.2 As a result of Rezolute completing enrollment in the study, XOMA | | | R ...